Immatics/$IMTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Immatics
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
Ticker
$IMTX
Sector
Primary listing
Employees
618
Headquarters
Website
Immatics Metrics
BasicAdvanced
$707M
-
-$0.76
1.02
-
Price and volume
Market cap
$707M
Beta
1.02
52-week high
$12.53
52-week low
$3.30
Average daily volume
785K
Financial strength
Current ratio
8.803
Quick ratio
8.404
Long term debt to equity
3.038
Total debt to equity
3.684
Interest coverage (TTM)
-90.81%
Profitability
EBITDA (TTM)
-91.873
Gross margin (TTM)
-28.93%
Net profit margin (TTM)
-57.45%
Operating margin (TTM)
-66.92%
Effective tax rate (TTM)
-4.87%
Revenue per employee (TTM)
$246,390
Management effectiveness
Return on assets (TTM)
-9.11%
Return on equity (TTM)
-17.54%
Valuation
Price to revenue (TTM)
4.424
Price to book
1.52
Price to tangible book (TTM)
1.53
Price to free cash flow (TTM)
-3.296
Free cash flow yield (TTM)
-30.34%
Free cash flow per share (TTM)
-1.766
Growth
Revenue change (TTM)
83.61%
Earnings per share change (TTM)
-18.39%
3-year revenue growth (CAGR)
-2.94%
3-year earnings per share growth (CAGR)
14.91%
What the Analysts think about Immatics
Analyst ratings (Buy, Hold, Sell) for Immatics stock.
Bulls say / Bears say
Immatics moved from a net loss of €94.6 million in 2023 to a net profit of €15.2 million in FY 2024, driven by one-time collaboration revenue and showing improved financial resilience (Reuters)
The company increased its cash reserves to €604.5 million as of December 31, 2024, extending its financial runway into the second half of 2027 to support ongoing R&D efforts (Reuters)
Immatics started enrolling patients in its pivotal SUPRAME Phase 3 trial for IMA203 in previously treated advanced melanoma, a key milestone toward a possible regulatory filing in 2027 (Reuters)
Revenue dropped 74.7% year-over-year to €4.74 million in Q2 2025, falling well short of analysts' consensus forecast of €13.81 million (Reuters)
Immatics posted an adjusted loss of €0.58 per share in Q2 2025, compared with the expected €-0.32, widening from a loss of €0.17 a year earlier and highlighting growing losses in clinical-stage operations (Reuters)
Q1 2025 revenue fell 38.6% year-over-year to €18.58 million, missing forecasts and showing instability in collaboration-derived revenue (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 30 Aug 2025.
Immatics Financial Performance
Revenues and expenses
Immatics Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Immatics stock?
Immatics (IMTX) has a market cap of $707M as of September 15, 2025.
What is the P/E ratio for Immatics stock?
The price to earnings (P/E) ratio for Immatics (IMTX) stock is 0 as of September 15, 2025.
Does Immatics stock pay dividends?
No, Immatics (IMTX) stock does not pay dividends to its shareholders as of September 15, 2025.
When is the next Immatics dividend payment date?
Immatics (IMTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Immatics?
Immatics (IMTX) has a beta rating of 1.02. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.